AR075812A1 - Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa - Google Patents
Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasaInfo
- Publication number
- AR075812A1 AR075812A1 ARP100100731A ARP100100731A AR075812A1 AR 075812 A1 AR075812 A1 AR 075812A1 AR P100100731 A ARP100100731 A AR P100100731A AR P100100731 A ARP100100731 A AR P100100731A AR 075812 A1 AR075812 A1 AR 075812A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyridin
- pyrrole
- difluoro
- carbonyl
- phenyl
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 2-methoxy-pyrimidin-5-yl Chemical group 0.000 abstract 7
- BQMPGKPTOHKYHS-UHFFFAOYSA-N 1h-pyrrole-2-carbonitrile Chemical compound N#CC1=CC=CN1 BQMPGKPTOHKYHS-UHFFFAOYSA-N 0.000 abstract 5
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000009036 biliary tract cancer Diseases 0.000 abstract 1
- 208000020790 biliary tract neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- YGNOYUCUPMACDT-UHFFFAOYSA-N dimethylsulfamic acid Chemical compound CN(C)S(O)(=O)=O YGNOYUCUPMACDT-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos {2,4-difluoro-3-[5-(2-metoxi-pirimidin-5-il)-1H-pirrol[2,3-b]piridin-3-carbonil-fenil}-amida del ácido propan-1-sulfonico, [3-(5-ciano-1H- pirrol[2,3b]piridin-3-carbonil)-2,4-difluoro-fenil]-amida del ácido propan-1-sulfonico, [3-(5-ciano-1H-pirrol[2,3-b]piridin-3-carbonil)-2-fluoro-fenil]-amida del ácido propan-1-sulfonico, N-[3-(5-ciano-1H-pirrol[2,3-b]piridin-3-carbonil)-2,4-difluoro-fenil]-2,5-difluoro-bencensulfonamida, N-[3-(5-ciano-1H-pirrol[2,3-b]piridin-3-carbonil)-2,4-difluoro-fenil]-3-fluoro-bencensulfonamida, [3-(5-ciano-1H-pirrol[2,3-b]piridin-3-carbonil)-2,4-difluoro-fenil]-amida del ácido pirrolidin-1-sulfonico, [3-(5-ciano-1H-pirrol[2,3-b]piridin-3-carbonil)-2,4-difluoro-fenil]-amida del ácido N,N-dimetilaminosulfonico, y sus sales, formulaciones, conjugados, derivados, formas y usos. En determinados aspectos y formas de realizacion, los compuestos descritos, o sus sales, formulaciones, conjugados, derivados y formas son activos para al menos una Raf proteína quinasa. También se describen métodos de uso de los mismos para tratar enfermedades y condiciones, incluyendo las enfermedades y condiciones asociadas con la actividad de Raf proteína quinasas, incluyendo melanoma, glioma, cáncer colorrectal, cáncer de tiroides, cáncer de pulmon, cáncer de ovario, cáncer de prostata y cáncer del tracto biliar.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15939009P | 2009-03-11 | 2009-03-11 | |
| US15940009P | 2009-03-11 | 2009-03-11 | |
| US15940209P | 2009-03-11 | 2009-03-11 | |
| US15939509P | 2009-03-11 | 2009-03-11 | |
| US15939209P | 2009-03-11 | 2009-03-11 | |
| US15940609P | 2009-03-11 | 2009-03-11 | |
| US15939609P | 2009-03-11 | 2009-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075812A1 true AR075812A1 (es) | 2011-04-27 |
Family
ID=42199540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100731A AR075812A1 (es) | 2009-03-11 | 2010-03-10 | Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8901301B2 (es) |
| EP (1) | EP2406259A1 (es) |
| JP (1) | JP2012520307A (es) |
| KR (1) | KR101663339B1 (es) |
| CN (1) | CN102421776A (es) |
| AR (1) | AR075812A1 (es) |
| AU (1) | AU2010224245B2 (es) |
| BR (1) | BRPI1011515A2 (es) |
| CA (1) | CA2755045A1 (es) |
| CO (1) | CO6620074A2 (es) |
| CR (1) | CR20110476A (es) |
| EC (1) | ECSP11011313A (es) |
| MA (1) | MA33181B1 (es) |
| MX (1) | MX2011009489A (es) |
| MY (1) | MY161861A (es) |
| NI (1) | NI201100168A (es) |
| NO (1) | NO20111241A1 (es) |
| PE (1) | PE20120184A1 (es) |
| RU (1) | RU2011141123A (es) |
| SG (2) | SG10201402977WA (es) |
| TW (1) | TW201036973A (es) |
| WO (1) | WO2010104945A1 (es) |
| ZA (1) | ZA201106599B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン |
| MX2011008303A (es) | 2009-04-03 | 2011-11-29 | Plexxikon Inc | Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas. |
| BR112012012156A2 (pt) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compostos e métodos para modulação de cinase, e indicações para esta |
| EP2501236B1 (en) | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
| MX2012007429A (es) * | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma. |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| JP2013526570A (ja) | 2010-05-14 | 2013-06-24 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 縮合二環式キナーゼ阻害剤 |
| EP2646054A4 (en) | 2010-12-02 | 2015-03-04 | Univ Pittsburgh | METHOD FOR THE TREATMENT OF A TUMOR WITH THE HELP OF AN ANTIBODY FOR SPECIFIC BINDING TO GRP94 |
| AU2012214762B2 (en) * | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2012149547A1 (en) | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| CA2836474A1 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| US9988687B2 (en) * | 2011-09-20 | 2018-06-05 | The George Washington Univeristy | Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants |
| WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014081760A1 (en) | 2012-11-20 | 2014-05-30 | Duke University | Methods of treating hemoglobinopathies |
| BR112015014752B1 (pt) | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
| RU2680100C9 (ru) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| DK3292123T3 (da) | 2015-05-06 | 2020-08-17 | Plexxikon Inc | Faste former af en forbindelse, der modulerer kinaser |
| US9745298B2 (en) | 2015-05-06 | 2017-08-29 | Plexxikon Inc. | Synthesis of a compound that modulates kinases |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA3129180A1 (en) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
| JP6921846B6 (ja) | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| BR112019028235B1 (pt) | 2017-07-25 | 2024-04-30 | Plexxikon, Inc. | Composições e seus métodos de preparação |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| TWI803530B (zh) | 2017-10-27 | 2023-06-01 | 美商普雷辛肯公司 | 調節激酶之化合物之調配物 |
| SG11202007143UA (en) | 2018-01-31 | 2020-08-28 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2019183145A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2019303986B2 (en) | 2018-07-16 | 2024-02-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| BR112021019957A2 (pt) | 2019-04-09 | 2021-12-07 | Plexxikon Inc | Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma |
| JP7639008B2 (ja) | 2020-01-15 | 2025-03-04 | ヘパリジェニックス ゲーエムベーハー | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 |
| TW202206422A (zh) | 2020-04-23 | 2022-02-16 | 美商普雷辛肯公司 | 用於ｃｄ７３調節之化合物及方法及其適應症 |
| AU2021263383A1 (en) | 2020-04-29 | 2022-11-24 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| WO2022040512A1 (en) | 2020-08-21 | 2022-02-24 | Plexxikon Inc. | Combinational drug anticancer therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140070676A (ko) | 2002-09-06 | 2014-06-10 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
-
2010
- 2010-03-10 RU RU2011141123/04A patent/RU2011141123A/ru unknown
- 2010-03-10 US US12/721,496 patent/US8901301B2/en active Active
- 2010-03-10 MA MA34228A patent/MA33181B1/fr unknown
- 2010-03-10 KR KR1020117023712A patent/KR101663339B1/ko not_active Expired - Fee Related
- 2010-03-10 CA CA2755045A patent/CA2755045A1/en not_active Abandoned
- 2010-03-10 JP JP2011554147A patent/JP2012520307A/ja not_active Withdrawn
- 2010-03-10 EP EP10708681A patent/EP2406259A1/en not_active Withdrawn
- 2010-03-10 PE PE2011001620A patent/PE20120184A1/es not_active Application Discontinuation
- 2010-03-10 CN CN2010800206771A patent/CN102421776A/zh active Pending
- 2010-03-10 BR BRPI1011515A patent/BRPI1011515A2/pt not_active Application Discontinuation
- 2010-03-10 AU AU2010224245A patent/AU2010224245B2/en active Active
- 2010-03-10 TW TW099106990A patent/TW201036973A/zh unknown
- 2010-03-10 SG SG10201402977WA patent/SG10201402977WA/en unknown
- 2010-03-10 SG SG2011063914A patent/SG174257A1/en unknown
- 2010-03-10 WO PCT/US2010/026816 patent/WO2010104945A1/en not_active Ceased
- 2010-03-10 MY MYPI2011004233A patent/MY161861A/en unknown
- 2010-03-10 MX MX2011009489A patent/MX2011009489A/es not_active Application Discontinuation
- 2010-03-10 AR ARP100100731A patent/AR075812A1/es unknown
-
2011
- 2011-08-09 EC EC2011011313A patent/ECSP11011313A/es unknown
- 2011-09-06 CR CR20110476A patent/CR20110476A/es unknown
- 2011-09-08 ZA ZA2011/06599A patent/ZA201106599B/en unknown
- 2011-09-09 NI NI201100168A patent/NI201100168A/es unknown
- 2011-09-12 CO CO11117856A patent/CO6620074A2/es not_active Application Discontinuation
- 2011-09-13 NO NO20111241A patent/NO20111241A1/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2406259A1 (en) | 2012-01-18 |
| AU2010224245B2 (en) | 2016-07-21 |
| TW201036973A (en) | 2010-10-16 |
| SG10201402977WA (en) | 2014-09-26 |
| MX2011009489A (es) | 2011-10-11 |
| CO6620074A2 (es) | 2013-02-15 |
| MA33181B1 (fr) | 2012-04-02 |
| CR20110476A (es) | 2012-01-04 |
| MY161861A (en) | 2017-05-15 |
| CA2755045A1 (en) | 2010-09-16 |
| NI201100168A (es) | 2012-01-11 |
| AU2010224245A1 (en) | 2011-09-29 |
| RU2011141123A (ru) | 2013-04-20 |
| PE20120184A1 (es) | 2012-03-28 |
| JP2012520307A (ja) | 2012-09-06 |
| US20100286178A1 (en) | 2010-11-11 |
| US8901301B2 (en) | 2014-12-02 |
| ZA201106599B (en) | 2014-02-26 |
| WO2010104945A1 (en) | 2010-09-16 |
| SG174257A1 (en) | 2011-10-28 |
| BRPI1011515A2 (pt) | 2016-03-29 |
| CN102421776A (zh) | 2012-04-18 |
| NO20111241A1 (no) | 2011-09-28 |
| KR20110125670A (ko) | 2011-11-21 |
| ECSP11011313A (es) | 2011-10-31 |
| KR101663339B1 (ko) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075812A1 (es) | Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa | |
| AR076105A1 (es) | Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa | |
| NI201100189A (es) | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| EA201100450A1 (ru) | Макроциклические пирамидины в качестве ингибиторов протеинкиназы | |
| ECSP109953A (es) | Derivados de piridazinona | |
| EA201200951A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| SV2007002813A (es) | Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables | |
| UY31272A1 (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
| EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина | |
| CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
| UY30816A1 (es) | Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones | |
| NZ599872A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| EA201101585A1 (ru) | 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные | |
| BRPI1013771A2 (pt) | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." | |
| BR112016005802A2 (pt) | conjugados de clorotoxina e métodos de seu uso | |
| PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
| CR20130374A (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos | |
| EA201290103A1 (ru) | Гетероциклические соединения и их использование | |
| ECSP088121A (es) | Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa | |
| NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
| CR10170A (es) | Triazolopiridazinas como moduladores de tirosina cinasa | |
| CL2009001032A1 (es) | Combinaciones de compuestos activos para controlar plagas animales; uso de las combinaciones; y procedimientos para controlar plagas animales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |